Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285178 | 0.98 | TAAR1 (0.74) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL27842525 | 0.98 | TAAR1 (0.74) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL895673 | 0.95 | TAAR1 (0.79) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| Hydrochloric Acid SCHEMBL1027480 | 0.93 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002162 | 0.91 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002124 | 0.89 | TAAR1 (0.69) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL42400 | 0.87 | TAAR1 (1.00) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL21002016 | 0.87 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| SCHEMBL29986862 | 0.87 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3AOC3 | |
| Hydrochloric Acid SCHEMBL10917318 | 0.85 | TAAR1 (0.96) | TAAR1CHRM2CHRM1CHRM3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727920-B1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-2727920-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-7479496-B2 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20050197325-A1 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005080376-A1 | SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-5661185-A | AN ALKOXYPHENYL-ALKYLUREA COMPOUND TREATING SLEEP DISORDER | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5541228-A | Melatonergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0706994-A1 | Melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197325-A1 | Substituted spiro azabicyclics as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | TAAR1 146/4885CHRM2 132/4885CHRM1 180/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | TAAR1 634/4885CHRM2 38/4885CHRM1 13/4885 |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | NRAS, RAF1, KRAS | TAAR1 3612/4885CHRM2 3219/4885CHRM1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.